Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2011

View Archived Issues

Combination of HER2 and VEGF peptidomimetics block angiogenesis and tumor cell growth

Atsttrin suppresses onset and symptoms of inflammatory arthritis in vivo

Immunohistochemical quantitation of LAMP-2 for the diagnosis of phospholipidosis

Superoxide dismutase [Cu-Zn] as a biomarker for drug-induced liver injury

Novel fluoroquinolone antibacterial agents patented by Achaogen

BioCryst presents new tyrosine-protein kinase JAK3 inhibitors

Novel HSP 90 inhibitors synthesized at Nerviano Medical Sciences

New inhibitors of dual specificity protein kinase TTK presented

Concert Pharma presents new deuterated xanthine derivatives

Dipraglurant enters phase IIa trial in Parkinson's disease and levodopa-induced dyskinesia

BARDA funds development of influenza therapy CS-8958

Metabolic Solutions Development begins phase IIa trial of MSDC-0602

Intercept Pharma reports phase II data on obeticholic acid in primary biliary cirrhosis

Polaris Pharma begins pivotal studies of ADI-PEG 20

Solvay to launch offer for Rhodia

MP-29-02 NDA filed in U.S. for seasonal allergic rhinitis

Eisai and PRISM collaborate on inhibitors of complex between CREB-binding protein and catenin beta-1

Ongoing phase II proof-of-concept trial evaluates LY-2828360 for osteoarthritic knee pain

IPI-926 reduces tumor growth in vivo and advances through clinical development

Lundbeck launches Sycrest in first European market

Algeta and Genzyme to collaborate on new approach to cancer treatment

QIAGEN reaches agreement to acquire Cellestis

Generex presents new strategic development plan

Anavex Life Sciences begins screening for phase I study of ANAVEX 2-73

Furiex Pharma evaluates PPD-10558 in phase II study in subjects with statin intolerance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...